

## Dennis M Black

Professor

Department of Epidemiology & Biostatistics, University of California, San Francisco, USA

### Curriculum Vitae



### ● Educational Background & Professional Experience

|              |                                                                                                |
|--------------|------------------------------------------------------------------------------------------------|
| 1987–Present | Professor, Department of Epidemiology & Biostatistics, University of California, San Francisco |
| 2005–2020    | Head, Division of Aging and Chronic Diseases, UCSF                                             |
| 1987         | PhD, Biostatistics, UC Berkeley                                                                |

### ● Research Interests

I have a strong interest in clinical aspects of osteoporosis particularly focused on randomized trials of new treatments. I was the study PI and first author of the Fracture Intervention Trial (FIT) of alendronate (Lancet, 1996) and its extension (JAMA 2006) which supported alendronate's regulatory approvals internationally. I was also the PI of the HORIZON PFT of zoledronate and its 2 extensions which supported its regulatory approval (NEJM 2007). I also played a large role in the phase III pre-approval studies for denosumab, raloxifene and abaloparatide. I am also the PI for the SABRE project which resulted in FDA approval in late 2025 of BMD as a surrogate endpoint for fracture in future trials of osteoporosis treatments (Lancet, D/E, 2020).

I have also published extensively on risk factors for fractures and atypical femur fractures (AFF) (NEJM, 2020) including the finding of the strong relationship of longer-term bisphosphonate treatment to AFF and of the 5-fold increase in AFF in Asians vs. Caucasians

Overall I have over 350 publications, mostly related to osteoporosis

### ● Publications

1. Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020.
2. Black DM, Delmas PD, Eastell R, et al HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007.
3. Black DM, Schwartz AV, et al;. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006.
4. Black DM, Cummings SR, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 (Citations: 4439).
5. Black DM, et al; Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020.